Navamedic ASA Financial report for Q2 2012
Navamedic's second quarter 2012 revenues saw a 25 per cent growth over the same period last year. Revenues were NOK 22.7 million compared to NOK 18.2 million in 2011. Nearly all revenues were generated by the Vitaflo business area, which experienced yet another all time high quarter.
EBITDA for the first quarter reached NOK 0.4 million, compared to NOK -1.1 million in the same period of 2011.
| (in NOK '000) | Q2 2012 | Q2 2011 | YTD 2012 | YTD 2011 | FY 2011 |
| Revenues | 22 701 | 18 190 | 43 289 | 34 967 | 71 299 |
| Gross Profit | 9 212 | 7 154 | 17 477 | 13 826 | 29 272 |
| Gross margin | 41 % | 39 % | 40 % | 40 % | 41 % |
| EBITDA | 437 | -1 096 | 495 | -2 078 | -2 639 |
| EBIT | -1 121 | -2 807 | -2 621 | -5 475 | -9 359 |
For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company. Through its subsidiary Vitaflo Scandinavia the Company is a distributor of a broad range of nutrition and pharmaceutical products in the Nordic markets. Navamedic is currently building up a generic pharmaceutical business for the Nordic, Dutch and Belgian markets based on its partnership with Aspen Healthcare of South Africa.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
The full report with tables and the presentation can be downloaded from the following links: